Spermosens (SPERM) Q1 2026 earnings summary

Executive summary

• Completed development of JUNO-Checked Generation 3, designed for high-volume clinical labs and initiated a new clinical validation study at RMC Malmö in Q2 2026, aiming for completion by year-end.

• Advanced partnership discussions, signing MOUs with Sapyen and RSI to expand male fertility diagnostics in the US and internationally.

• Commercial strategy remains partner-driven, focusing on license agreements as the primary revenue path.

Financial highlights

• Net sales for Q1 2026 were SEK 0 thousand, unchanged year-over-year.

• Operating loss for Q1 2026 was SEK -2,175 thousand, slightly higher than SEK -2,063 thousand in Q1 2025.

• Cash and cash equivalents at quarter-end were SEK 4,481 thousand, down from SEK 13,147 thousand at Q1 2025.

• Equity at period end was SEK 30,235 thousand, compared to SEK 38,100 thousand in Q1 2025.

• Earnings per share for Q1 2026 was SEK -0.001, improved from SEK -0.002 in Q1 2025.

Outlook and guidance

• Clinical validation of JUNO-Checked Generation 3 expected to complete by end of 2026.

• Ambition to convert partnership discussions into formal agreements during 2026.

• Financing runway expected through Q1 2027, with additional capital anticipated from TO6 warrants in late 2026.